Drug Type Monoclonal antibody |
Synonyms Anti-CLDN3 monoclonal antibody - Abion, α-ABN501, ABN 501 + [1] |
Target |
Action inhibitors |
Mechanism CLDN3 inhibitors(claudin 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Small Cell Lung Cancer | Preclinical | South Korea | 22 Mar 2024 | |
| Ovarian Cancer | Preclinical | South Korea | 14 Apr 2022 |






